Dupilumab, a mAb targeting IL-4 receptor alpha (IL-4R?), markedly improves disease severity in patients with atopic dermatitis. However, the effect of IL-4R? blockade on dynamics circulating skin-homing T cells, which are crucial players pathologic mechanism dermatitis, has not been studied yet. In addition, it remains unknown whether dupilumab treatment induces long-lasting T- and B-cell polar...